Summary

In Canada the increasing prevalence of diabetes has been a significant driver for the insulin delivery devices market. As the number of people diagnosed with diabetes rises, the demand for insulin and related delivery devices also increases. On-going advancements in insulin delivery device technology have played a crucial role in driving market growth. Innovations such as smart insulin pens, wearable insulin pumps, and integrated continuous glucose monitoring systems enhance the ease of use and convenience for patients. The aging population in Canada is more susceptible to diabetes, and as the demographic of elderly individuals increases, there is a corresponding rise in the demand for insulin and insulin delivery devices. Older individuals may find certain devices more convenient and easier to use. During the forecast time frame, rising diabetes prevalence in Canada is anticipated to fuel market expansion for insulin delivery devices. For example, according to Diabetes Canada (March 2022), there are currently over 5.7 million Canadians with a diagnosis of type 1 or type 2 diabetes, and an additional 11.7 million Canadians have prediabetes, which can progress to type 2 diabetes if left untreated. Over the course of the projected period, rising demand for insulin delivery devices is anticipated to support market expansion in Canada. For example, Insulet Corporation stated in January 2021 that the Omnipod DASH insulin management system would be available in Canada to help persons with type 1 or type 2 diabetes controls their blood sugar levels. The increasing incidence of type 2 diabetes, often associated with lifestyle factors, contributes to the demand for insulin and insulin delivery devices. The need for effective and convenient treatment options is particularly relevant in managing type 2 diabetes cases.

According to the research report "Canada Insulin Delivery Devices Market Overview, 2028," published by Bonafide Research, the Canada Insulin Delivery Devices market is expected to reach market size of more than USD 900 Million by 2028. The use of continuous glucose monitoring systems has gained traction in Canada. Integrated CGM systems with insulin pumps and pens offer real-time insights into glucose levels, allowing for better diabetes management. The trend is towards more seamless and integrated solutions. The integration of insulin delivery devices with mobile health apps and digital platforms is a trend that provides patients and healthcare professionals with valuable data. This integration supports remote monitoring, adherence tracking, and facilitates communication between patients and their healthcare teams. The trend towards disposable insulin pens is observed in Canada, offering convenience and ease of use. These pens eliminate the need for vial and syringe preparation, providing a more straightforward solution for patients and potentially reducing the risk of errors in insulin administration. Smart insulin pens, equipped with Bluetooth connectivity and dose tracking capabilities, are gaining popularity. These devices can sync with mobile apps, providing users with real-time information on their insulin doses, historical data, and reminders for medication adherence. The application of 3D printing technology in manufacturing insulin delivery devices is an emerging trend. This technology allows for more personalized and intricate designs, potentially leading to the development of devices tailored to individual patient needs. Innovations in smart packaging for insulin are being explored. This includes packaging with temperature sensors and indicators to ensure the proper storage conditions of insulin, especially during transportation and storage.

Based on product market is majorly segmented into insulin pens, insulin pumps, insulin pen needles, insulin syringes and others insulin delivery devices(insulin transdermal patches, insulin inhalers, insulin jet injection). Insulin syringes are often considered a cost-effective option for insulin delivery. In healthcare systems where cost is a significant consideration, the affordability of insulin syringes may contribute to their popularity and growth in the market. Insulin syringes have a long history of established use in diabetes management. Healthcare professionals and patients are often familiar with the use of insulin syringes, and this familiarity can influence their continued use and growth in the market. The disposable nature of insulin syringes reduces the risk of contamination and infection, and it aligns with sustainability trends in healthcare. Disposable insulin syringes are convenient for patients and healthcare providers, and their use contributes to infection control measures. Insulin syringes are widely available across healthcare settings. Their ubiquity makes them a commonly used method for insulin delivery, especially in regions where other types of insulin delivery devices may be less accessible. Insulin syringes are well-suited for use in home care settings. Their simplicity makes them a practical choice for patients who self-administer insulin at home, contributing to the growth of the segment in home care markets. In addition, Canada, like many other developed countries, has an aging population. Older adults are more susceptible to chronic conditions such as diabetes. The Home Care segment may lead the market as older individuals prefer to receive care in the comfort of their homes, and managing diabetes at home aligns with their healthcare preferences. Cultural factors and societal preferences can influence healthcare choices. If there is a cultural shift towards valuing and preferring home-based care, it can drive the adoption of insulin delivery devices for home use, leading to the growth of the Home Care segment.

In terms of indication market includes diabetes, pregnancy, cardiovascular disorders & hypertension, respiratory diseases, hearing disorders, cancer, movement disorders, wound care and other indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV). Cancer patients often experience changes in their metabolism, leading to conditions like diabetes. The coexistence of cancer and diabetes is not uncommon. As a result, individuals with cancer may require insulin to manage their blood sugar levels. Some cancer treatments, such as certain chemotherapy drugs or corticosteroids, can induce diabetes or exacerbate pre-existing diabetes. Patients undergoing cancer treatments might require insulin therapy to manage their blood glucose levels. Pancreatic cancer is often associated with diabetes, as the pancreas plays a crucial role in insulin production. The treatment of pancreatic cancer, which may involve surgery or other interventions, can impact insulin production and lead to the need for insulin therapy. Some cancers can affect hormones and insulin sensitivity, leading to diabetes or insulin resistance. This can necessitate the use of insulin delivery devices for effective diabetes management Cancer patients may have comorbidities such as diabetes, and managing both conditions simultaneously requires careful attention. Insulin delivery devices become crucial in ensuring precise insulin administration for diabetes control.

Recent Developments
• In December 2021, NuGen Medical Devices received Health Canada approval for its needle-free injection system and accessories, also known as InsuJet, which gives access to safe, pain-free, cost-effective drug delivery for the millions of patients who suffer from diabetes, or other chronic illnesses.
• In July 2020, Medtronic launched MiniMed Mio Advance Infusion sets for diabetes that offer a more convenient and faster insulin pump experience made commercially available in Canada.
• In November 2020, Tandem Diabetes Care announced Health Canada approval of the t:slim X2 insulin pump with control-IQ advanced hybrid closed-loop technology.

Considered in this report:
• Geography: Canada
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:
• Canada Insulin Delivery Devices market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Insulin Pens
• Insulin Pumps
• Insulin Pen Needles
• Insulin Syringes
• Others Insulin Delivery Devices (Insulin transdermal patches, insulin inhalers, insulin jet injection)

By Indication
• Diabetes
• Pregnancy
• Cardiovascular Disorders & Hypertension
• Respiratory Diseases
• Hearing Disorders
• Cancer
• Movement Disorders
• Wound Care

By End User
• Home Care
• Hospitals & Clinics
• Others

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Insulin Delivery Devices industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.

ページTOPに戻る

Table of Contents